<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00014768</url>
  </required_header>
  <id_info>
    <org_study_id>199/15797</org_study_id>
    <secondary_id>UUSOM-IRB-7922-00</secondary_id>
    <nct_id>NCT00014768</nct_id>
  </id_info>
  <brief_title>Study of Metabolic Effects of Pregnancy in Women With Cystic Fibrosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Center for Research Resources (NCRR)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Compare the clinical status of pregnant vs non-pregnant women with cystic&#xD;
      fibrosis.&#xD;
&#xD;
      II. Determine glucose tolerance during each trimester of pregnancy in these women.&#xD;
&#xD;
      III. Evaluate peripheral insulin sensitivity in these women. IV. Evaluate whole body protein&#xD;
      turnover and hepatic glucose production in these women.&#xD;
&#xD;
      V. Determine resting energy expenditure in these women.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: Patients undergo a glucose tolerance test over 3 hours and a potassium body&#xD;
      scan on day 1. Patients undergo an indirect calorimetry over 20 minutes on day 2. Patients&#xD;
      receive stable-labeled leucine and stable-labeled glucose IV over 3 hours followed by insulin&#xD;
      and glucose IV over 4-4.5 hours on day 2 using the hyperinsulinemic euglycemic clamp&#xD;
      technique.&#xD;
&#xD;
      Blood and breath samples are collected to measure glucose tolerance, peripheral insulin&#xD;
      sensitivity, and whole body protein turnover. Hepatic glucose production is measured by mass&#xD;
      spectrophotometry.&#xD;
&#xD;
      Patients maintain a 3-day food journal before pregnancy, during each trimester, and after&#xD;
      pregnancy.&#xD;
&#xD;
      Patients undergo each study during the final 2 weeks of each trimester of pregnancy and then&#xD;
      at 6 months post-partum.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>February 2001</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Natural History</observational_model>
  </study_design_info>
  <enrollment>36</enrollment>
  <condition>Cystic Fibrosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glucose</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
          -  Diagnosis of cystic fibrosis (CF) and pregnant OR Age, weight, and body mass index&#xD;
             matched non-pregnant CF woman or pregnant non-CF woman&#xD;
&#xD;
          -  No infection with Burkholderia cepacia&#xD;
&#xD;
          -  FEV1 at least 60%&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
          -  At least 3 weeks since prior corticosteroids&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
          -  Hepatic: No more than one transaminase level greater than 10% above normal&#xD;
&#xD;
        Other:&#xD;
&#xD;
        Pregnant non-CF controls:&#xD;
&#xD;
          -  No cigarette smokers&#xD;
&#xD;
          -  No history of gestational diabetes mellitus&#xD;
&#xD;
          -  No type 1 or 2 diabetes&#xD;
&#xD;
          -  No other chronic illness&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dana S. Hardin</last_name>
    <role>Study Chair</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah School of Medicine</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2002</verification_date>
  <study_first_submitted>April 10, 2001</study_first_submitted>
  <study_first_submitted_qc>April 10, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>cardiovascular and respiratory diseases</keyword>
  <keyword>cystic fibrosis</keyword>
  <keyword>genetic diseases and dysmorphic syndromes</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

